SCHEMBL10162359

SCHEMBL10162359

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(F)c3)nc3c(F)cnn23)s1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.47
ADAMTS4 O75173 1/20 0.47
MMP3 P08254 1/20 0.47
CACNA1G O43497 4/20 0.41
CACNA1H O95180 4/20 0.41
CACNA1I Q9P0X4 4/20 0.41
MAPK1 P28482 3/20 0.39
MET P08581 1/20 0.39
MAOB P27338 1/20 0.38
RPS6KA1 Q15418 1/20 0.38
PDPK1 O15530 3/20 0.38
SCD O00767 1/20 0.38
EPHX2 P34913 1/20 0.37
PDGFRA P16234 1/20 0.37
CHRM4 P08173 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162353 0.93 MMP13 (0.48) MMP13ADAMTS4MMP3CACNA1GCACNA1H
SCHEMBL10162378 0.93 MMP13 (0.45) MMP13ADAMTS4MMP3MAPK1RPS6KA1
SCHEMBL10162405 0.92 ADAMTS4 (0.44) MMP13ADAMTS4MMP3
SCHEMBL10162390 0.92 MMP13 (0.56) MMP13ADAMTS4MMP3MAPK1RPS6KA1
SCHEMBL10162379 0.89 MMP13 (0.47) MMP13ADAMTS4MMP3MAPK1RPS6KA1
SCHEMBL10162388 0.89 MMP13 (0.44) MMP13ADAMTS4MMP3CACNA1GCACNA1H
SCHEMBL10162333 0.88 PDPK1 (0.41) MMP13CACNA1GCACNA1HCACNA1IMAPK1
SCHEMBL10162500 0.86 MMP13 (0.40) MMP13ADAMTS4MMP3CACNA1GCACNA1H
SCHEMBL10162395 0.86 ADAMTS4 (0.41) MMP13ADAMTS4MMP3
SCHEMBL10162387 0.85 ADAMTS4 (0.44) MMP13ADAMTS4MMP3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.